“This webcast series will present some of the research that is currently impacting the genetic field,” said Andreas Scherer, President and CEO of Golden Helix. “We are honored to host a platform for the competition winners to share their important work with the community.”
The webcast topics are quite varied, ranging from human to animal studies and cover topics from GWAS, to candidate gene and whole exome analysis to DNA and RNA sequencing. The webcast schedule is as follows:
Tuesday, May 13th – Examining the Genetic Underpinnings of Commonly Comorbid Language Disorders: Dyslexia and Language Impairment, by John Eicher, Yale University.
July 22nd – Identifying Metabolic Thresholds and Genomic Markers for Optimal Energy Balance in Healthy, Productive Transition Cows, by Dr. Heather Huson, Cornell University.
September 23rd – Identification of Single Nucleotide Polymorphisms (SNPs) Involved in the Determination of Craniofacial Morphology, by Mark Barash, Bond University.
October 8th – Allele Specific Expression in Human Disease, by Dr. Kenneth Kaufman, Cincinnati Children’s Hospital Medical Center.
November 18th – Identification of Rare Variants in Neurodegenerative Disease, by Dr. EunRan Suh, University of Pennsylvania.
December 10th – Multiple Hybrid Sterility Loci, Genomic Incompatibilities, and Transcriptomic Misregulation Identified in Feline Interspecies Breeds, by Brian Davis, National Human Genome Research Institute.
For an invitation or more information on a particular webcast or the series, please contact Golden Helix directly at email@example.com.
About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 15 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With our solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications.